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ABSTRACT
Background: The ability to identify high risk head and neck cancer (HNC) patients 
with disseminated disease prior to presenting with clinically detectable metastases 
holds remarkable potential. A fraction of circulating tumour cells (CTCs) are invasive 
cancer cells which mediate metastasis by intravasation, survival and extravasation 
from the blood stream to metastatic sites. CTCs have been cleared by the FDA for 
use as surrogate markers of overall survival and progression free survival for breast, 
prostate and colorectal cancers using the CellSearch® system. However, the clinical 
significance of CTCs in head and neck cancer patients has yet to be determined. There 
has been a significant shift in CTC enrichment platforms, away from exclusively single 
marker selection, to epitope-independent systems.
Methods: The aim of this study was to screen advanced stage HNC patients 
by the CellSearch® platform and utilise two other epitope-independent approaches, 
ScreenCell® (microfiltration device) and RosetteSep™ (negative enrichment), to 
determine how a shift to such methodologies would enable CTC enrichment and 
detection.
Results: In advanced stage HNC patients, single CTCs were detected in 8/43 
(18.6%) on CellSearch®, 13/28 (46.4%) on ScreenCell® and 16/25 (64.0%) by 
RosetteSep™ (the latter could also detect CTC clusters). Notably, in patients with 
suspicious lung nodules, too small to biopsy, CTCs were found upon presentation. 
Moreover, CTCs were readily detected in advanced stage HNC patients. 
Conclusion: The epitope-independent platforms detected higher CTC numbers 
and clusters. Further studies are needed to ascertain whether CTCs can be used as 
independent prognostic markers for HNCs.
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INTRODUCTION
Head and neck squamous cell carcinomas 
(HNSCCs) account for the sixth commonest cause of 
cancer mortality worldwide with an incidence of 650,000 
cases annually [1, 2]. The combined 5 year survival rate 
is 50%, with poor control of distant metastatic spread 
[2]. Approximately 50-60% of HNSCC patients develop 
locoregional recurrence of which a further 20% progress 
to distant metastasis (DM), accounting for an increasing 
rate of treatment failure [3]. Human Papillomavirus (in 
particular HPV-16,-18) has been etiologically linked with 
HNCs and has a better general prognosis at presentation 
compared to HPV-negative HNCs [4-6]. In fact, patients 
with HPV+ oropharyngeal cancers have better outcomes 
than their HPV-negative counterparts at similar advanced 
stages of disease [5]. Five year survival rates for this same 
cohort is much better than the HPV-negative patients [7]. 
Whilst DM rates in HPV+ and HPV- patients appears to 
be quite similar [8, 9], HPV+ DM tends to occur after 
longer time periods, in unusual and multiple sites (lungs, 
brain, kidney, skin, and skeletal muscle) [4, 10, 11]. This 
may have clinical ramifications with the requirement for 
longer clinical follow-ups and monitoring in HPV-positive 
patients.
The dissemination of cancer from the primary 
tumour to lymph nodes and distant organs, such as the 
lungs, liver and bone portends poorer patient prognosis 
[12]. The spread of cancer cells can occur through 
invasion of local tissue, lymphatics, and/or through the 
blood circulation as CTCs [12, 13]. Moreover, CTCs 
can also be derived from metastatic deposits [14]. CTCs 
can be found in the blood as single cells and/or cell 
clusters, which can vary in their degree of epithelial and 
mesenchymal characteristics [14-16]. CTCs are believed 
to later extravasate from the blood and colonize distant 
organs, forming clinically detectable metastases [14]. The 
detection of CTCs in blood samples, coined as, ‘liquid 
biopsy’ is considered as a surrogate marker for patient 
response to treatment, thereby directing therapeutic 
decisions [14, 17, 18]. 
Current diagnostic methods for staging include 
clinical assessment, sophisticated imaging and often 
biopsy of the primary site as well as suspected metastasis. 
When metastases are clinically evident, treatment is 
palliative. There is a need for better prognostic markers 
to determine patients who are at an increased risk of 
locoregional recurrence and/or distant metastatic disease 
[1, 19-21]. CTC numbers detected in the blood have shown 
correlation with tumour staging and advanced disease in 
breast, prostate, colorectal and lung cancers [2, 22]. More 
recently, the isolation, culture and drug sensitivity of 
CTCs has also come to the fore opening up avenues for 
targeted treatment strategies and personalized medicine 
[23-26]. Limited CTC studies in patients with HNC were 
carried out in small patient cohorts. There is also a lack of 
standardized methodologies for CTC enumeration in HNC 
and it remains clinically unvalidated [1, 2, 12, 19, 27, 28]. 
We hypothesize that the enumeration of CTC from 
HNSCC patients can be increased by using epitope-
independent detection platforms. The aim of this study 
was to evaluate (i) CellSearch® (FDA-approved CTC 
platform) and (ii) epitope-independent technologies: 
ScreenCell® (microfiltration) and RosetteSep™ (negative 
enrichment) in patients with locally advanced HNSCC to 
determine the CTC capture efficiency of such assays. The 
ScreenCell® and RosetteSep™ assays were followed up by 
immunocytochemistry for the detection of CTCs. EGFR 
expression was incorporated into the CTC panel as it has 
shown to be detectable on the cell surface of HNSCC 
CTCs [29, 30] . To our knowledge, this is the largest 
paired patient study conducted across multiple CTC 
detection platforms in HNC patients. Our data reveals that 
the epitope-independent platforms detect higher single 
CTC numbers as well as CTC clusters. Larger clinical 
studies are warranted to ascertain whether CTCs can be 
used as independent prognostic markers for HNCs.
RESULTS
Patient characteristics
A total of 58 patients were included in this study. 
Patient characteristics are shown in Table 1. The median 
age was 60 years (range 40-87); men (n = 50), women 
(n = 8). The most distinctive histology was mucosal oral 
cavity SCC (68.1%) followed by oropharyngeal (22.4%), 
nasopharyngeal (6.9%) and laryngeal SCC (8.6%). The 
bulk of patients presented with tumour grade ranging 
from T4 (55.1%) to advanced nodal spread (N2A-C) 
(62.1%). The HPV-status was determined in all patients (n 
= 58) and found to be positive for HPV-16 (n = 14). DM 
was assessed by a multidisciplinary team (MDT) at the 
PAH by combining CT/PET-CT and MRI scans. 98.3% 
of the patients were found to be radiographically M0. 
CTC presence was determined from new patients upon 
presentation to the clinic, prior to therapy. Upon patient 
follow up, two patients in the study had succumbed to 
their disease. One patient (T4N2CM0 oropharyngeal SCC, 
HPV-16 positive) treated with chemotherapy (Docetaxel, 
cisplatin and 5-fluorouracil) died within 11 days and the 
other patient (T4N2BM0 supraglottic SCC) who had 
mildly avid FDG-PET uptake on the in the right apex of 
the lung died in 24 days (See Figure 4). Notably, both 
patients presented with CTC clusters in their blood post 
RosetteSep™ enrichment. 
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Spike in experiments were performed to serve as 
positive controls for the three platforms
When FaDu cells (EpCAM+ cells) of clinically 
relevant numbers (<100 cells) were spiked into blood 
(10ml) and recovery studies performed, CellSearch® 
consistently detected over 95% of the cells, ScreenCell® 
60% and RosetteSep™ 70%. It should be noted that as 
the detection of tumour cells on the CellSearch®  is fully 
automated whereas the epitope-independent techniques 
are manually processed post enrichment which including 
multiple wash steps.
CellSearch®
The CellSearch® system was able to successfully 
identify CTCs in 8/43 (18.6%) patients with locally 
advanced HNSCC before therapy (Table 2 and Figure 
1). The number of CTCs detected per 7.5 mL of blood 
ranged from 0 to 28 (0 CTC: n = 35 patients; 1 CTC: n = 5 
patients; 2 CTCs: n = 2 patients, 28 CTCs: n = 1 patient). 
All 8 CTC-positive patients detected by the CellSearch® 
were HPV-16 negative. CTCs were not detected in any 
of the bloods analysed from normal healthy volunteers 
(NHV) controls (n = 4). There was no significant 
correlation between the presence of CTCs (p = 0.73; 
Pearson’s chi-squared test) and tumour staging. In the 
patient presenting with 28 CTCs/7.5ml whole blood, the 
patient had extensive nodal disease and suspicious lung 
nodules. 
ScreenCell®
The ScreenCell® platform was able to successfully 
capture CTCs on the filter membrane in 13/28 (46.4%) 
patients with locally advanced HNSCC before therapy 
(Table 2, Figure 2). The number of single CTCs detected 
per 3 mL of blood ranged from 0 to 3 (0 CTC: n = 14 
patients; 1 CTC: n = 3 patients; 2 CTCs: n = 6 patients; 3 
CTCs: n = 1 patient) and CTC clusters (5 or more cells) 
n = 5 patients. In two CTC-positive patients detected by 
ScreenCell®, there was concurrent HPV-16 positivity and 
both patients had base-of-tongue (BOT) SCC and were 
stage T2-4, N2b. CTCs were not detected in NHV control 
samples (n = 4). There was a significant correlation (p 
= 0.04; Pearson’s chi-squared test) found between the 
presence of CTCs before therapy and the patient tumour 
staging.
RosetteSep™
RosetteSep™ was able to successfully negatively 
deplete whole blood and enrich for CTCs in 16/25 (64.0%) 
patients with locally advanced HNSCC before therapy 
(Table 2, Figure 3). The number of single CTCs ranged 
from 0 to 3, (0 CTC: n = 9 patients; 1 CTC: n = 6 patients; 
2 CTCs: n = 5 patients; 3 CTCs: n = 1 patients), CTC 
doublets (2 CTCs) and CTC clusters (CTC doublets: n = 
1 patients; CTC clusters: n = 4 patients). A few patients 
had concurrent single CTCs and CTC clusters detectable 
post enrichment. Notably, in one of the patients who 
died during the study period, RosetteSep™ was able to 
successfully isolate CTC clusters from only 3ml of whole 
blood (Figure 3). 6/25 (24%) of the HNSCC patients were 
HPV-16 positive with 4/6 (66.7%) presenting with single 
CTCs and CTC clusters. CTCs were not detected in 8 
NHV control samples. There was no significant correlation 
between the presence of CTCs and tumour staging (p = 
0.918299; Pearson’s chi-squared test). 
Table 1: Patient demographic (n=58) including 
Age, Gender, Tumour Site, Nodal Status, Distant 
Metastases, HPV Status.
Variables N
Total 58 (100%)
Gender  
Male 50 (86.2%)
Female 8 (13.8%)
Age, y  
<60 19 (32.8%)
>60 39 (67.2%)
Anatomic site of primary  
Oral Cavity 36 (68.1%)
Oropharyngeal 13 (22.4%)
Nasopharyngeal 4 (6.9%)
Laryngeal 5 (8.6%)
Tumour Size  
T1 2 (3.4%)
T2 4 (6.9%)
T3 9 (15.5%)
T4 32 (55.1%)
Tx 11 (19.0%)
Nodal spread  
N0 21 (36.2%)
N1 1 (1.7%)
N2a-c 36 (62.1%)
Distant metastases  
M0 57 (98.3%)
M1 1 (1.7%)
HPV status  
HPV-positive 14 (24.1%)
HPV-negative 44 (75.9%)
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Head to head comparison between platforms
There was concordance between the CellSearch® 
and ScreenCell® platforms in detecting CTCs across 
paired bloods from the same patient for 2 patients (tumour 
stage T4, nodal spread N2b) (Supplementary Figure 6). 
However, four further patients (tumour stage T3-4, N2b-c) 
showed detectable CTCs on the CellSearch® only and 11 
patients (tumour stage T2-T4, N0-N2b) showed CTCs on 
the ScreenCell® only, including CTC clusters. 
When ten paired advanced stage HNSCC patient 
bloods were enriched using the CellSearch® and 
RosetteSep™ platforms, CTCs were detected in 1/10 by 
CellSearch® and 6/10 by RosetteSep. In the case where the 
CellSearch® detected 1 CTC, it was similarly detectable 
post RosetteSep™ enrichment (T3N2b supraglottic 
SCC). The RosetteSep™ platform was able to detect CTC 
clusters more readily and with higher detection rates in the 
analysed patient cohort. 
In all patients presenting with CTC clusters (n = 
4), outcomes were poor. Two patients died in less than 
a month and the other two patients were referred onto 
palliative care due to worsening outcomes.
DISCUSSION
This is the first study to compare CTC detection 
using three CTC enrichment platforms for HNCs. 
In our study, CTCs were detected using CellSearch® 
(18.6%), ScreenCell® (46.4%) and RosetteSep™ (64.0%) 
respectively. In the head to head comparisons, ScreenCell® 
was able to capture more CTCs (single, clusters) than the 
CellSearch® across 26 HNC patient samples. This might 
be due to a low or lack of EpCAM expression on CTCs 
of these patients possibly linked to engagement into EMT, 
whereby CellSearch® would not detect these CTCs [1, 
31, 32]. More importantly, the ScreenCell® platform only 
processes 3ml of blood per sample compared to the 7.5 
mL used in CellSearch®, therefore, in less than half the 
volume of blood, ScreenCell® is able to isolate tumour 
cells more readily than the gold standard, CellSearch® 
technology. This higher CTC capture efficiency has been 
highlighted in several studies [33-35]. The CTCs detected 
by CellSearch® only could be ‘small CTCs’ which have 
been known to be found in circulation [31], which could 
be able to pass through the ScreenCell® Filters and thereby 
remain undetectable. Importantly, the patient prognosis 
was found to be poorer when CTCs were detected 
(irrespective of enrichment platform), more so when CTC 
clusters were present in circulation. 
In previous HNSCC studies, the CellSearch® 
system was able to detect CTCs in 8/49 (16%) and 3/9 
HNSCC patients [2, 19]. Buglione et al reported higher 
CTC numbers were found in stage IV than in stage I-III 
HNSCC patients [36]. He et al found that CTCs were 
more frequently detected in patients with nodal stage 2 
and 3 than with nodal stage 0 or 1 [2]. In the study by 
Nichols et al., CTCs were detected in 6/15 (40%) of 
HNSCC patient who were queried with lung nodules [37]. 
In our study, CTCs were more readily detectable across 
all three platforms in tumour stages T2-T4 and nodal 
Table 2: Correlation between tumour stage and CTC presence across the CellSearch®, ScreenCell® and RosetteSep™ 
platforms. 
CTC positive: Cytokeratin (8, 18, 19) positive, negative for CD45, larger than leukocytes with intact nuclei. CTC negative: 
Negative for cytokeratin (8,18,19), positive for CD45.
Oncotarget5www.impactjournals.com/oncotarget
stages N2A-C, highlighting a higher volume of disease, 
consistent with previously published literature. It has been 
shown that in metastatic cancers, 20-50% of patients are 
negative for CTC in blood samples of 10ml and below. 
Therefore, higher blood volumes, with more frequent 
intervals may be required to properly access the burden of 
disease in HNC patients [31].
When paired blood samples from HNSCC patients 
were compared between the CellSearch® and RosetteSep™ 
(n = 10), RosetteSep™ processing and subsequent 
staining was able to detect CTCs more frequently than 
CellSearch® (60% vs 10% respectively). More importantly, 
RosetteSep™ was able to enrich for CTC clusters, which 
are proposed to have a higher metastatic potential and 
intravasate into blood via leaky blood vessels or at site 
of vascular mimicry [12, 15, 32]. It should be noted that 
with the post enrichment cytospins for RosetteSep™, 
there is an inherent cell loss and morphologic changes 
during the spinning steps and subsequent washes [38], 
which could translate to higher actual patient CTC counts 
post enrichment. CTC clusters and/or circulating tumour 
microemboli (CTMs) have been shown to be 23 to 50 
times more likely to establish distant metastases than 
single CTCs [15]. These CTC clusters were found to be 
more resistant than single cells in circulation and cleared 
faster from circulation to distant sites [15]. 
From spiking experiments, CellSearch® was the 
platform most consistently able to recover over 95% 
of tumour cells when compared to the ScreenCell® and 
RosetteSep™. This is likely due to the automation of the 
Figure 1: Patient CTCs detected by the CellSearch® system. The second row shows a nucleated, CD45 positive cell below the 
CTC which is a leukocyte below the patient CTC. The varying morphology of patient CTCs is evident from Figure 1 where some CTCs 
appear epithelial like in morphology whereas some appear fibroblast-like and mesenchymal. Imaged on the Celltracks Analyzer II ® system. 
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CellSearch® technology and the increased wash steps 
and handling steps post enrichment with the epitope-
independent techniques. ScreenCell® is further limited 
with a total blood volume of only 3ml. Furthermore, 
we could show that FaDu cells are functional post 
RosetteSep™ enrichment whereas with CellSearch®, the 
CTCs can only be enumerated. The RosetteSep™ process 
maintained cells in a proliferative and viable state. This is 
important for any downstream CTC cultures, which have 
shown potential across multiple tumour types including 
the creation of CTC cell lines [14, 23] 
It is important to note that, CellSearch® showed 
clinical relevance in the CTCs detected by the use of 
the EpCAM based-platform and threshold values were 
generated for metastatic breast (mBC), prostate (mPC), 
colorectal (mCRC) where (0-4 CTCs) for mBC, mPC, and 
(0-2 CTCs) for mCRC had favourable patient outcomes 
whereas (≥5 CTCs) for mBC, mPC and (≥3 CTCs) for 
mCRC had unfavourable patient outcomes. These large 
cross-institutional studies have not been done for HNCs. 
Moreover, the clinical significance of the CTCs captured 
by the epitope-independent technologies needs to be 
analysed to determine whether an increased capture of 
CTCs in circulation are actually of clinically relevant 
CTCs [39].
CONCLUSIONS
There has been a significant shift in the CTC 
enrichment field where epitope-independent CTC 
isolation has been shown to capture a greater population 
of the CTCs in the circulation in an unbiased fashion. 
Moreover, recent technological improvements in the 
field of microfluidics has given rise to fast and efficient 
CTC enrichment [14, 40, 41]. This study highlights 
the shift in the field from marker based technologies 
(EpCAM-CellSearch®), to marker-independent isolation. 
If the presence of CTCs predicts for the development of 
clinically evident metastases, identifying these before 
metastases are clinically evident may allow for escalation 
of systemic treatment. With the improvements in isolation 
Figure 2: Presentation of selected CTCs in the peripheral blood of HNC patients. Image gallery presenting CTCs isolated by 
the ScreenCell® microfiltration system: Cytokeratin, EGFR, DAPI-positive but CD45 negative with a cell size larger than the pore size of 
the filter (approximately 7µm). Imaged on the Olympus IX3 inverted microscope. Scale bar represents 50µm.
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technologies and higher CTC capture efficiencies, it 
potentially allows ex-vivo CTC propagation [14, 23]. In 
patients with established metastatic disease, culturing 
CTCs will allow for the testing of drug sensitivities, which 
in turn may help guide the choice of systemic palliative 
chemotherapy and reduce the morbidity from ineffective 
treatment. More studies are needed in the HNC field, to 
investigate the character of the circulating tumour cells, 
determine whether HPV-infection plays a pivotal role, 
and provide threshold CTC counts for HNSCC patients in 
order to determine patient prognosis.
MATERIALS AND METHODS
Patient cohort
Ethics approval was obtained by the Metro South 
Health Service District Human Research Ethics Committee 
in accordance with the NHMRC’s guidelines (HREC/12/
QPAH/381) to collect blood from the Princess Alexandra 
Hospital (PAH). This study has UQ (2009000779) 
and QUT (1400000617) ethics approval. After written 
informed consent was obtained from the participants, 
blood samples were obtained from patients. Advanced 
Figure 3: Presentation of selected CTCs in the peripheral blood of HNC patients. Image gallery presenting CTCs captured 
by the RosetteSep™ system: Cytokeratin, EGFR, DAPI-positive but CD45 negative. Imaged on the Olympus IX3 inverted microscope. 
Scale bars represent 50 µm.
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stage treatment-naïve HNSCC patients were identified 
as tumour stage T3/4 with locoregional nodal spread. A 
10 ml of blood was collected either at the clinic or prior 
to surgery into CellSave (Immunicon Inc., Huntingdon 
Valley, USA) preservative tube for processing on the 
CellSearch®. A 10 ml BD Vacutainer K2E tube (EDTA) 
(BD-Plymouth, UK) for processing on the ScreenCell® 
and 10ml Heparin tube (BD-Plymouth, UK) for processing 
with RosetteSep™. The CellSave tube was stored at room 
temperature and processed within 72 hours and the BD 
Vacutainer EDTA and Heparin tubes processed within 4 
hours. CTC detection was performed using CellSearch®, 
ScreenCell® and RosetteSep™ platforms (from November 
2013 until November 2015). Gender, age, race and 
ethnicity, smoking status, alcohol consumption, tumour 
staging, nodal spread, distant metastases assessment by 
radiologist and HPV status were collated per HNSCC 
patient. The comparative schematic is presented in 
Supplementary Figure 1. 
Cell culture
All cell lines used in these experiments were 
obtained from the ATCC (Manassas, VA). The following 
HNSCC cell lines were selected: FaDu (ATCC®HTB43TM) 
Figure 4: CT scan images of selected HNC patients presenting with suspicious HNC metastasis. Bloods were taken upon 
presentation of these patients to clinic and CTCs assessed. Patient presenting with A. bony metastasis B., C., D. multiple suspicious lung 
metastasis E., F. lung nodule which increased in size over 37 days.
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and CAL27 (ATCC®CRL2095TM) (Passage range 
6-10). Cells were cultured under standard conditions in 
humidified incubators at 37oC, 5% CO2. To avoid the 
influence of culture media, all culture media conditions 
were standardized to RPMI-1640-Glutamax (Life 
Technologies, Inc) supplemented with 10% foetal bovine 
serum (Life Technologies, Inc) and 1% Penicillin-
Streptomycin (Life Technologies, Inc).
Enrichment and detection of circulating tumour 
cells using CellSearch® (Veridex, NJ, USA)
Whole blood (7.5 ml) from CellSave Blood 
collection tubes (Veridex, NJ, USA) was mixed with 
6.5ml of CellTracksTM system buffer and centrifuged at 
800 x g for 10 minutes and then placed on the AutoPrepTM 
system (CellSearch® Circulating tumour cell kit). The 
AutoPrep system added the appropriate reagents and 
magnetically separated the cells. The reagents include 
ferrofluid particles coated with EpCAM antibodies 
(positive selection) and the characterization antibodies 
(anti-CD45) conjugated to phycoerytherin (PE) and 
DAPI (nuclear stain). The cells were then quantitatively 
analysed with the CellTracks Analyzer. EpCAM-positive, 
cytokeratin-positive, CD45-negative cells with an intact 
nucleus (DAPI+) that is positioned at least 50% within 
the cytoplasm, and has a diameter of at least 4x4 µm were 
defined as CTCs. Each sample was analysed independently 
by two readers and questionable events evaluated until 
consensus was reached. The results were reported as 
number of CTCs/7.5ml whole blood (Figure 1).
To determine whether the platform was capable 
of detecting cells from HNSCC spiking experiments 
using the epithelial FaDu cell line (ATCC®HTB43TM) 
and CAL27 (ATCC®CRL2095TM) was performed 
(Supplementary Figure 2 and 3). As a control, 4 further 
healthy volunteers were screened and no CTC-events were 
observed.
Enrichment of circulating tumour cells using 
ScreenCell®
Whole blood (6 ml) was collected in EDTA 
vacutainers and processed within 4 hours. ScreenCell® 
Cyto (ScreenCell®, France) microfiltration devices were 
used to capture CTCs according to the manufacturers 
protocol. Briefly, 3 ml of peripheral blood was mixed 
with 4 ml of ScreenCell® FC2 dilution buffer. The 
content was homogenised by inverting 5 times followed 
by an incubation of 8 minutes at room temperature. 
The 7 ml of diluted blood was then filtered through the 
ScreenCell® Cyto (ScreenCel®l, France) (filter pore size 
7.5µm) device by using vacuum force provided by a 9 ml 
vacutainer. This step was followed by rinsing the filter 
with 1.6 ml of 1xPBS. The circular filter was then dried 
on whatman paper and stained. Initial staining was with 
H&E (Harris) followed by immunofluorescent staining 
for cytokeratins 8/18/19, CD45 (CellSearch® antibody 
mixture) (1:6 dilution), EGFR (Biolegend, AY13) and 
DAPI (Figure 2). Imaging performed using an Olympus 
IX3 inverted microscope. Furthermore, to verify whether 
the platform was capable of detecting cells from HNSCC, 
spike-in experiments were conducted with the FaDu cell 
line (ATCC®HTB43TM) (Supplementary Figure 4). As a 
control, 4 healthy volunteers were screened and no CTC-
events were observed. 
Enrichment of circulating tumour cells using 
RosetteSep®
Whole blood collected in lithium heparin tubes 
(StemCell Technologies, Vancouver, Canada) was 
incubated with RosetteSep® Human CD45 depletion 
cocktail (Stemcell Technologies, Vancouver, British 
Columbia, Canada) at 50 µl/mL of whole blood and 
incubated for 20 minutes at room temperature. Then 
CTC separation is made in a density gradient using 
SepMate™-50 mL tubes containing Lymphoprep™ 
(Stemcell Technologies, Vancouver, Canada). For 
microscopy, the enriched cells were cytospun (1000 rpm, 
5mins) onto slides and stained with a combination of 
antibodies to cytokeratins 8/18/19, CD45 (CellSearch® 
antibody mixture) (1:6 dilution), EGFR (Biolegend, 
AY13) and DAPI and analysed using an Olympus IX3 
inverted microscope (Figure 3). Furthermore, to verify 
whether this method was capable of detecting cells from 
HNSCC, spike-in experiments were conducted with the 
FaDu cell line (ATCC®HTB43TM) (Supplementary Figure 
5). To determine the viability of the cells post enrichment, 
the spike-in tumour cell fraction was put into standard 
media (RPMI-1640 Glutamax), supplemented with 10% 
foetal bovine serum and 1% Penicillin-Streptomycin and 
incubated (Life Technologies, Inc) at 37OC and 5% CO2.
Detection of CTCs 
CTCs were visualized using immunofluorescence 
on the ScreenCell® filters and RosetteSepTM enriched 
cytospins using a number of markers. We classified cells 
as CTCs if they were positive for EGFR, cytokeratins 
8/18/19, negative for CD45, had intact nuclei and 
morphologically different from leucocytes. CTCs tended 
to be larger than the surrounding leukocytes, however this 
should not be used as a general rule as CTCs have been 
shown to vary in size.
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